The company is reaffirming the adjusted 2023 EPS guidance range of $5.55 to $5.75, and long-term adjusted EPS growth rate of 5% to 7% through 2027 off the 2023 midpoint of $5.65. Management does not forecast reported GAAP EPS and related long-term growth rates.
Oppenheimer Maintains Outperform on Syros Pharmaceuticals, Lowers Price Target to $3
Oppenheimer analyst Mark Breidenbach maintains Syros Pharmaceuticals (NASDAQ:SYRS) with a Outperform and lowers the price target from $9 to $3.
